ABLE Financial Group’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$409K Buy
1,850
+120
+7% +$26.2K 0.06% 160
2026
Q2
$337K Sell
1,730
-461
-21% -$95.5K 0.06% 168
2026
Q1
$492K Buy
2,191
+77
+4% +$19.2K 0.1% 137
2025
Q4
$509K Sell
2,114
-134
-6% -$34.3K 0.1% 128
2025
Q3
$615K Sell
2,248
-57
-2% -$15.6K 0.13% 112
2025
Q2
$595K Buy
2,305
+277
+14% +$66.1K 0.14% 109
2025
Q1
$454K Sell
2,028
-611
-23% -$143K 0.13% 110
2024
Q4
$604K Buy
2,639
+72
+3% +$17.3K 0.18% 89
2024
Q3
$627K Sell
2,567
-299
-10% -$66.8K 0.19% 82
2024
Q2
$549K Buy
2,866
+715
+33% +$145K 0.2% 83
2024
Q1
$426K Sell
2,151
-428
-17% -$78.4K 0.17% 97
2023
Q4
$444K Sell
2,579
-197
-7% -$30.3K 0.19% 92
2023
Q3
$410K Buy
2,776
+1,632
+143% +$295K 0.21% 88
2023
Q2
$250K Buy
+1,144
New +$255K 0.13% 119

Other funds holding RMD

ABLE Financial Group's RMD Position: Q3 2026 in Review

ABLE Financial Group increased its ResMed (RMD) stake by 6.9% in Q3 2026, buying an estimated $26.2K and bringing the position to 1,850 shares worth $409K. The position accounts for 0.06% of the portfolio, ranked #160.

ABLE Financial Group first reported a position in RMD in Q2 2023 and has held it in 14 quarters since. The position peaked at $627K in Q3 2024. 167 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • ABLE Financial Group held 1,850 shares of ResMed worth $409K as of Q3 2026.
  • ABLE Financial Group bought 120 ResMed shares in Q3 2026, an estimated $26.2K.
  • ResMed made up 0.06% of ABLE Financial Group's portfolio in Q3 2026, its #160 holding.
  • ABLE Financial Group first reported a position in ResMed in Q2 2023 and has held it in 14 quarters since.
  • ABLE Financial Group's ResMed position peaked at $627K in Q3 2024.
  • 167 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on ABLE Financial Group's 13F filing for Q3 2026, filed 14 Oct 2026.